

**Risk Algorithm Using Serial Biomarker Measurements In
Screen-Detected Cancers Compared With a Single-Three
Collaborative Trial of Ovarian Cancer Screening**

Journal of Clinical Oncology

33, 2062-2071

DOI: [10.1200/jco.2014.59.4945](https://doi.org/10.1200/jco.2014.59.4945)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Highly-accurate metabolomic detection of early-stage ovarian cancer. <i>Scientific Reports</i> , 2015, 5, 16351.	1.6	65
2	Biomarkers for diagnosis: looking for change. <i>Biomarkers in Medicine</i> , 2015, 9, 1275-1277.	0.6	1
3	Data Mining of Gene Arrays for Biomarkers of Survival in Ovarian Cancer. <i>Microarrays (Basel)</i> , Tj ETQq0 0 0 rgBT /Overlock 10 ₃ Tf 50 662	1.4	3
4	Fallopian Tube Ligation or Salpingectomy as Means for Reducing Risk of Ovarian Cancer. <i>AMA Journal of Ethics</i> , 2015, 17, 843-848.	0.4	5
5	Biomarker potential of CA-125 enhanced. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 437-437.	12.5	3
6	Opportunistic salpingectomy for ovarian cancer prevention. <i>Gynecologic Oncology Research and Practice</i> , 2015, 2, 5.	3.6	28
7	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 668-679.	12.8	839
8	Diagnosis of ovarian cancer. <i>BMJ, The</i> , 2015, 351, h4443.	3.0	68
9	Clinically Meaningful Use of Blood Tumor Markers in Oncology. <i>BioMed Research International</i> , 2016, 2016, 1-10.	0.9	49
10	Ovarian Cancer Screening There May Be Light at the End of the Tunnel?. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 608-609.	1.2	1
11	Improved Detection Rate of Ovarian Cancer Using a 2-Step Triage Model of the Risk of Malignancy Index and Expert Sonography in an Outpatient Screening Setting. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1062-1069.	1.2	9
12	Ovarian cancer screening: UKCTOCS trial. <i>Lancet, The</i> , 2016, 387, 2602-2603.	6.3	4
13	External validation of the IOTA ADNEX model performed by two independent gynecologic centers. <i>Gynecologic Oncology</i> , 2016, 142, 490-495.	0.6	46
14	Breast Cancer Survivorship. , 2016, , .		3
15	High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma. <i>Journal of Ovarian Research</i> , 2016, 9, 41.	1.3	28
16	Squeezing more value from the analytes we have: personal baselines for multiple analytes in serial DBS. <i>Bioanalysis</i> , 2016, 8, 1539-1542.	0.6	9
17	Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 597-611.	1.9	44
18	A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort. <i>Clinical Cancer Research</i> , 2016, 22, 4664-4675.	3.2	80

#	ARTICLE	IF	CITATIONS
19	An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 319-327.	1.1	26
20	Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. <i>Annals of Oncology</i> , 2016, 27, v103-v110.	0.6	292
21	Evaluating the risk of ovarian cancer before surgery using the ADNEX model: a multicentre external validation study. <i>British Journal of Cancer</i> , 2016, 115, 542-548.	2.9	66
22	Protein Z: A putative novel biomarker for early detection of ovarian cancer. <i>International Journal of Cancer</i> , 2016, 138, 2984-2992.	2.3	41
23	Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies. <i>EBioMedicine</i> , 2016, 10, 137-149.	2.7	34
24	Ovarian cancer. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16061.	18.1	761
25	Evaluation and Management of Ultrasonographically Detected Ovarian Tumors in Asymptomatic Women. <i>Obstetrics and Gynecology</i> , 2016, 127, 848-858.	1.2	33
26	Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. <i>Cancer Prevention Research</i> , 2016, 9, 713-720.	0.7	7
27	Farletuzumab in the treatment of ovarian cancer. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 327-331.	0.5	0
28	Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 945-956.	6.3	791
29	Definition of Specificity in a Screening Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 198-198.	0.8	1
30	Reply to P.F. Pinsky, C.P. Crum, and M.W. McIntosh et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 201-202.	0.8	0
31	The genetic prediction of risk for gynecologic cancers. <i>Gynecologic Oncology</i> , 2016, 141, 10-16.	0.6	41
32	Importance of serial CA125 measurements over an absolute cut-off value for the detection of asymptomatic ovarian cancer in high-risk patients. <i>International Journal of Gynecology and Obstetrics</i> , 2016, 133, 239-240.	1.0	2
33	The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 454-468.	13.9	227
34	Survival benefit of epithelial ovarian cancer in hormone replacement therapy users: Could it be explained by socio-economic status?. <i>Maturitas</i> , 2016, 86, 26-27.	1.0	0
35	Metabolomics of biomarker discovery in ovarian cancer: a systematic review of the current literature. <i>Metabolomics</i> , 2016, 12, 1.	1.4	57
36	Should we screen for ovarian cancer? A commentary on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) randomized trial. <i>Gynecologic Oncology</i> , 2016, 141, 191-194.	0.6	14

#	ARTICLE	IF	CITATIONS
37	Genetic screening for gynecological cancer: where are we heading?. <i>Future Oncology</i> , 2016, 12, 207-220.	1.1	11
38	Preventing Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 198-199.	0.8	7
39	Ovarian Cancer Early Detection Needs Better Imaging, Not Better Algorithms or Biomarkers. <i>Journal of Clinical Oncology</i> , 2016, 34, 199-200.	0.8	7
40	Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. <i>British Journal of Cancer</i> , 2017, 116, 501-508.	2.9	86
41	Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk – Combined Results from Two Screening Trials. <i>Clinical Cancer Research</i> , 2017, 23, 3628-3637.	3.2	99
42	Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer. <i>Nature Reviews Cancer</i> , 2017, 17, 199-204.	12.8	318
43	Moving towards population-based genetic risk prediction for ovarian cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 855-858.	1.1	5
44	Ovarian Cancer Knowledge Among Advanced Providers in a University Setting. <i>Journal for Nurse Practitioners</i> , 2017, 13, e221-e229.	0.4	0
45	Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 100-121.	157.7	529
46	Efficacy of salpingectomy at hysterectomy to reduce the risk of epithelial ovarian cancer: a systematic review. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 880-889.	1.1	22
47	Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 145, 122-129.	0.6	21
50	British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 213, 123-139.	0.5	64
51	Screening for Thyroid Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1888.	3.8	500
52	The role of biomarkers in the management of epithelial ovarian cancer. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 577-591.	1.5	102
53	Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer. <i>Tumor Biology</i> , 2017, 39, 101042831769913.	0.8	16
55	Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk. <i>Obstetrics and Gynecology</i> , 2017, 130, e146-e149.	1.2	52
56	Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5912-5922.	3.2	47
57	Risk of chronic liver disease in post-menopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMC Public Health</i> , 2017, 17, 603.	1.2	11

#	ARTICLE	IF	CITATIONS
58	A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. <i>British Journal of Cancer</i> , 2017, 117, 666-674.	2.9	47
59	The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 270.e1-270.e9.	0.7	55
60	Ovarian Cancer: Improving Outcomes: A Primary Care Perspective. , 0, , 204-209.		0
61	Comparison of Fecal Calprotectin Methods for Predicting Relapse of Pediatric Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2017, 2017, 1-10.	0.8	30
62	A multiplex platform for the identification of ovarian cancer biomarkers. <i>Clinical Proteomics</i> , 2017, 14, 34.	1.1	25
63	The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. <i>Genome Medicine</i> , 2017, 9, 116.	3.6	122
64	Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1411-1420.	0.8	148
65	A Combinatorial Proteomic Biomarker Assay to Detect Ovarian Cancer in Women. <i>Biomarkers in Cancer</i> , 2018, 10, 1179299X1875664.	3.6	2
66	Ovarian Cancer Prevention and Screening. <i>Obstetrics and Gynecology</i> , 2018, 131, 909-927.	1.2	176
67	Outcome of elevated CA125 values from primary care following implementation of ovarian cancer guidelines. <i>Family Practice</i> , 2018, 35, 199-202.	0.8	8
68	Association between skirt size and chronic liver disease in post-menopausal women: a prospective cohort study within the United Kingdom Trial of Ovarian Cancer Screening (UKCTOCS). <i>BMC Public Health</i> , 2018, 18, 409.	1.2	0
69	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	178
70	A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2018, 149, 585-591.	0.6	53
71	Screening for ovarian cancer: imaging challenges and opportunities for improvement. <i>Ultrasound in Obstetrics and Gynecology</i> , 2018, 51, 293-303.	0.9	69
72	Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2018, 13, 134-138.	0.5	21
73	Steady, relentless progress towards effective, safe screening for early detection of cancer of the ovary. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 526-528.	1.1	0
74	Diagnose, Staging und Grading. , 2018, , .		0
76	Assessing Pelvic Epithelial Cancer Risk and Intercepting Early Malignancy. , 2018, , 844-864.		0

#	ARTICLE	IF	CITATIONS
77	Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 297-316.	157.7	433
78	Steps towards effective gynaecological cancer screening. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 538-540.	12.5	1
79	Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: a cohort study from British Columbia, Canada. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 172.e1-172.e8.	0.7	27
80	Genetic Evidence for Early Peritoneal Spreading in Pelvic High-Grade Serous Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 58.	1.3	7
81	Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population. <i>Clinical Cancer Research</i> , 2018, 24, 4726-4733.	3.2	39
83	Moonshot Objectives: Catalyze New Scientific Breakthroughsâ€”Proteogenomics. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 121-125.	1.0	7
84	Novel Approaches to Ovarian Cancer Screening. <i>Current Oncology Reports</i> , 2019, 21, 75.	1.8	56
85	<p>Efficacy and safety of intraperitoneally administered resveratrol against rat orthotopic ovarian cancers</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 6113-6124.	0.9	6
86	The 14q32 maternally imprinted locus is a major source of longitudinally stable circulating microRNAs as measured by small RNA sequencing. <i>Scientific Reports</i> , 2019, 9, 15787.	1.6	7
87	Engineering State-of-the-Art Plasmonic Nanomaterials for SERSâ€Based Clinical Liquid Biopsy Applications. <i>Advanced Science</i> , 2019, 6, 1900730.	5.6	112
88	Potential early clinical stage colorectal cancer diagnosis using a proteomics blood test panel. <i>Clinical Proteomics</i> , 2019, 16, 34.	1.1	44
89	Cancer Screening Markers: A Simple Strategy to Substantially Reduce the Sample Size for Validation. <i>Medical Decision Making</i> , 2019, 39, 130-136.	1.2	2
90	Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection. <i>Cancer Prevention Research</i> , 2019, 12, 171-184.	0.7	12
91	Biomarkers of Gynecological Cancers. , 2019, , 133-150.		0
93	High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. <i>International Journal of Molecular Sciences</i> , 2019, 20, 952.	1.8	381
94	Selected Medical Interventions in Women With a Deleterious Brca Mutation: A Population-Based Study in British Columbia. <i>Current Oncology</i> , 2019, 26, 17-23.	0.9	13
95	Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 184-210.	157.7	448
96	Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. <i>Cancer Prevention Research</i> , 2019, 12, 391-400.	0.7	17

#	ARTICLE	IF	CITATIONS
97	Applying Machine Learning of Erythrocytes Dynamic Antigens Store in Medicine. <i>Frontiers in Molecular Biosciences</i> , 2019, 6, 19.	1.6	2
98	Complete salpingectomy versus tubal ligation during cesarean section: a systematic review and meta-analysis. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021, 34, 3794-3802.	0.7	9
99	Blood-based protein biomarkers in breast cancer. <i>Clinica Chimica Acta</i> , 2019, 490, 113-127.	0.5	51
100	Whole-Blood DNA Methylation Markers in Early Detection of Breast Cancer: A Systematic Literature Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 496-505.	1.1	24
101	Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 56.e1-56.e17.	0.7	25
102	Genetic Factors. , 2020, , 180-208.e11.		4
103	Carcinoma of the Ovaries and Fallopian Tubes. , 2020, , 1525-1543.e7.		0
104	Ultrasound screening of ovarian cancer. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2020, 41, .	0.3	5
105	Human epididymis protein 4 antigen-antibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer. <i>Cancer</i> , 2020, 126, 725-736.	2.0	21
106	Screening and Early Detection. , 2020, , 375-398.e7.		1
107	Biomarkers and Strategies for Early Detection of Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2504-2512.	1.1	53
108	Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. <i>Cancers</i> , 2020, 12, 1931.	1.7	18
109	Statistical approaches using longitudinal biomarkers for disease early detection: A comparison of methodologies. <i>Statistics in Medicine</i> , 2020, 39, 4405-4420.	0.8	4
110	Diagnostic accuracy of serum insulin-like growth factor-binding protein 2 for ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1762-1767.	1.2	4
111	CA125 and Ovarian Cancer: A Comprehensive Review. <i>Cancers</i> , 2020, 12, 3730.	1.7	174
112	The changing landscape of cancer in the USA – opportunities for advancing prevention and treatment. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 631-649.	12.5	32
113	The Human Body as a Super Network: Digital Methods to Analyze the Propagation of Aging. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 136.	1.7	24
114	Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in <i>BRCA1/2</i> : A Review of Secondary Prevention Guidelines. <i>Journal of Oncology</i> , 2020, 2020, 1-13.	0.6	20

#	ARTICLE	IF	CITATIONS
115	Ovarian cancer screening: Current status and future directions. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 65, 32-45.	1.4	68
116	Reducing Ovarian Cancer Mortality Through Early Detection: Approaches Using Circulating Biomarkers. <i>Cancer Prevention Research</i> , 2020, 13, 241-252.	0.7	44
117	Developing a mass spectrometry-based assay for the ovarian cancer biomarker CA125 (MUC16) using suspension trapping (STrap). <i>Analytical and Bioanalytical Chemistry</i> , 2020, 412, 6361-6370.	1.9	9
118	The Emerging Role of Neutral Argon Plasma (PlasmaJet) in the Treatment of Advanced Stage Ovarian Cancer: A Systematic Review. <i>Surgical Innovation</i> , 2020, 27, 299-306.	0.4	12
119	Examining indicators of early menopause following opportunistic salpingectomy: a cohort study from British Columbia, Canada. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 221.e1-221.e11.	0.7	28
120	Prophylactic salpingectomy for the prevention of ovarian cancer: Who should we target?. <i>International Journal of Cancer</i> , 2020, 147, 1245-1251.	2.3	17
121	Improved early detection of ovarian cancer using longitudinal multimarker models. <i>British Journal of Cancer</i> , 2020, 122, 847-856.	2.9	60
122	Population Screening for Inherited Predisposition to Breast and Ovarian Cancer. <i>Annual Review of Genomics and Human Genetics</i> , 2020, 21, 373-412.	2.5	31
123	The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease. <i>BMC Gastroenterology</i> , 2020, 20, 104.	0.8	5
124	Screening the population for ovarian cancer detection: history, reality and prospects. <i>Profilakticheskaya Meditsina</i> , 2021, 24, 103.	0.2	0
125	Aptamer-Based Detection of Circulating Targets for Precision Medicine. <i>Chemical Reviews</i> , 2021, 121, 12035-12105.	23.0	294
126	Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1353-1361.	1.4	25
127	Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 2182-2193.	6.3	313
128	General population screening for ovarian cancer. <i>Lancet, The</i> , 2021, 397, 2128-2130.	6.3	17
129	Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada. <i>Gynecologic Oncology</i> , 2021, 162, 461-468.	0.6	8
130	Ovarian-Cancer-Associated Extracellular Vesicles: Microenvironmental Regulation and Potential Clinical Applications. <i>Cells</i> , 2021, 10, 2272.	1.8	17
131	False-positive screening events and worry influence decisions about surgery among high-risk women.. <i>Health Psychology</i> , 2019, 38, 43-52.	1.3	3
132	The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. <i>PLoS Medicine</i> , 2020, 17, e1003295.	3.9	73

#	ARTICLE	IF	CITATIONS
133	Novel risk models for early detection and screening of ovarian cancer. <i>Oncotarget</i> , 2017, 8, 785-797.	0.8	13
134	Drugs Repurposing in High-Grade Serous Ovarian Cancer. <i>Current Medicinal Chemistry</i> , 2020, 27, 7222-7233.	1.2	5
135	Beta-Caryophyllene Suppresses Ovarian Cancer Proliferation by Inducing Cell Cycle Arrest and Apoptosis. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 1530-1537.	0.9	23
136	Management of Ovarian Masses in the Older Woman. , 2016, , 1-10.		0
137	Follow Up of Patients with Germline Mutations in High Risk Predisposition Genes. , 2016, , 53-63.		0
139	Management of Ovarian Masses in the Older Woman. , 2017, , 549-558.		0
140	Utilization of Tumor Markers in Adnexal Masses: A Review of Current Literature. <i>Current Women's Health Reviews</i> , 2018, 15, 3-11.	0.1	0
141	Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage. , 2019, , e.1-e.39.		0
142	A Combined Analysis of Serum Growth Differentiation Factor-15 and Cancer Antigen 15-3 Enhances the Diagnostic Efficiency in Breast Cancer. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2021, 32, 363-376.	0.7	5
143	External Validation of the Assessment of Different NEoplasias in the adneXa Model Performance in Evaluating the Risk of Ovarian Carcinoma Before Surgery in China: A Tertiary Center Study. <i>Journal of Ultrasound in Medicine</i> , 2022, 41, 2333-2342.	0.8	3
148	GBP5 and ACSS3: two potential biomarkers of high-grade ovarian cancer identified through downstream analysis of microarray data. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 4601-4613.	2.0	0
149	Molecular markers in cancer. <i>Clinica Chimica Acta</i> , 2022, 532, 95-114.	0.5	5
150	Too Much Medicine: Time to Stop Indiscriminate Cancer Screening. <i>Annals of the Academy of Medicine, Singapore</i> , 2015, 44, 194-196.	0.2	1
151	Screening for Ovarian Cancer in the General Population: State of Art and Perspectives of Clinical Research. <i>Anticancer Research</i> , 2022, 42, 4207-4216.	0.5	2
152	Beyond glyco-proteomicsâ€”Understanding the role of genetics in cancer biomarkers. <i>Advances in Cancer Research</i> , 2023, , 57-81.	1.9	0
153	Metabolic biomarkers in cancer. , 2023, , 173-198.		5
154	Early Cancer Biomarker Discovery Using DIA-MS Proteomic Analysis of EVs from Peripheral Blood. <i>Methods in Molecular Biology</i> , 2023, , 127-152.	0.4	3
165	Ovarian Cancer Screening in the General Population. , 2023, , 77-94.		0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------